Welcome to our dedicated page for Mineralys Therapeutics SEC filings (Ticker: MLYS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Phase 2 blood-pressure endpoints, FDA meeting timelines, stock-based compensation for a science-driven team鈥擬ineralys Therapeutics鈥� SEC disclosures are packed with biotech jargon that can overwhelm even seasoned analysts. If you have ever scrolled through a 300-page report looking for a single dosing update, you know the challenge. That complexity makes Mineralys Therapeutics insider trading Form 4 transactions and clinical milestones difficult to spot when seconds matter.
Stock Titan solves the problem. Our AI reads every Mineralys Therapeutics quarterly earnings report 10-Q filing the moment it hits EDGAR, extracts cash-runway tables, and flags enrollment progress so you don鈥檛 have to. It highlights Mineralys Therapeutics Form 4 insider transactions real-time, translates risk-factor language into plain English, and stitches together cross-references so you get Mineralys Therapeutics SEC filings explained simply. Whether you need a quick Mineralys Therapeutics earnings report filing analysis or are understanding Mineralys Therapeutics SEC documents with AI before a meeting, our platform delivers.
Use the dashboard to monitor upcoming trials stated in the Mineralys Therapeutics annual report 10-K simplified, drill into pipeline funding clues hidden in the Mineralys Therapeutics proxy statement executive compensation, or receive instant alerts when an executive executes Mineralys Therapeutics executive stock transactions Form 4. Material study readouts? They surface through Mineralys Therapeutics 8-K material events explained. AG真人官方-time updates, concise AI-powered summaries, and form-specific filters turn dense documents into actionable insights鈥攆reeing you to focus on whether lorundrostat鈥檚 next data cut could move the share price.
Mineralys Therapeutics entered into an underwriting agreement to sell 9,803,921 shares of common stock at a public offering price of $25.50 per share, with the underwriters purchasing the shares from the company at $23.97 per share. The company expects net proceeds of approximately $234.7 million, or about $269.9 million if the underwriters' 30-day option to buy an additional 1,470,588 shares is exercised in full. The offering is expected to close on September 4, 2025, subject to customary closing conditions.
The transaction is being conducted under previously declared Form S-3 registration statements and is accompanied by customary representations, indemnities and closing conditions. The filing includes the underwriting agreement and counsel opinion as exhibits. The company also included a forward-looking statements caution noting that actual results may differ due to market conditions and closing risks.
Mineralys Therapeutics (MLYS) is offering securities under a $500,000,000 registration, including resale registration for 8,888,924 shares related to a $120.0 million private placement completed at $13.50 per share (including pre-funded warrants). The company is an emerging growth and smaller reporting company and its common stock trades on Nasdaq under MLYS (last reported price $12.69 on March 15, 2024). An underwriter option allows purchase of up to 1,470,588 additional shares for 30 days. Mineralys is a clinical-stage biopharma developing lorundrostat, an oral aldosterone synthase inhibitor; a Phase 2 proof-of-concept trial in 200 subjects reported a clinically meaningful, statistically significant blood-pressure reduction with once-daily dosing and good tolerability. The prospectus discloses broad use-of-proceeds discretion, a 60-day lock-up for insiders, extensive international selling restrictions, and tax and dividend treatment details for non-U.S. holders.
Mineralys Therapeutics (MLYS) is offering $175,000,000 of common stock and has an existing shelf registration to offer up to $500,000,000 of various securities, including common stock, preferred stock, debt securities, warrants and units. The prospectus registers resale of up to 8,888,924 shares by selling stockholders; Mineralys will not receive proceeds from those resales. The company previously completed a private placement for aggregate gross proceeds of approximately $120.0 million consisting of 8,339,169 shares at $13.50 and 549,755 pre-funded warrants.
Mineralys is a clinical-stage biopharmaceutical company developing lorundrostat, an oral aldosterone synthase inhibitor initially for uncontrolled and resistant hypertension and cardiorenal conditions. In a Phase 2 proof-of-concept trial (Target-HTN, 200 subjects) lorundrostat produced a clinically meaningful, statistically significant blood pressure reduction and was well tolerated. The filing emphasizes high investment risk and discloses Nasdaq listing (MLYS) and recent prices of $12.69 (Mar 15, 2024) and $15.48 (Aug 29, 2025).
Mineralys Therapeutics insider activity: Dr. David Malcom Rodman, the company's Chief Medical Officer, exercised options and sold common stock under a Rule 10b5-1 plan. On 08/12/2025 he exercised stock options to acquire 6,349 shares at an exercise price of $1.08, increasing his direct beneficial ownership to 104,256 shares. The related option grants vesting details are stated: 25% vested on 07/12/2022 with the remainder vesting in 36 monthly installments. On 08/13/2025 he sold 11,365 shares at a weighted-average price of $12.9333, with sale prices ranging from $12.590 to $13.223. The transactions were effected pursuant to a 10b5-1 trading plan adopted on 10/25/2024.
Mineralys Therapeutics (MLYS) Schedule 13G/A reports that BioDiscovery 6 FPCI, Andera Partners and two Andera managing partners, Stephane Bergez and Francois Xavier Mauron, together may be deemed to beneficially own 2,765,976 shares of common stock, representing 4.2% of the class based on 65,175,287 shares outstanding as of May 8, 2025. The shares are held of record by BioDiscovery 6; voting and dispositive authority is shared (no sole voting or dispositive power reported). The filers disclaim status as a group. The filing discloses Paris as the reporting persons' principal address and includes a joint filing agreement as an exhibit.
Catalys Pacific entities and an individual reported shared beneficial ownership of 8,978,954 shares, representing 13.5% of Mineralys Therapeutics, Inc. The filing states this total includes 8,903,838 shares held of record by Catalys Pacific Fund, LP and 75,116 shares underlying options exercisable within 60 days of June 30, 2025. The reporting group consists of Catalys Pacific Fund, LP; Catalys Pacific Fund GP, LP; Catalys Pacific, LLC; and Brian Taylor Slingsby, who is the managing director and signed the filing on August 14, 2025. Ownership figures are based on 66,295,184 shares outstanding as disclosed by the issuer.
Mineralys Therapeutics (MLYS) filed a Form 144 to notify a proposed sale of 11,365 shares of common stock, with an aggregate market value of $146,987.47. The shares were acquired on 08/12/2024 by cash exercise of employee stock options from Mineralys Therapeutics, Inc., and the proposed sale is to be executed through Merrill Lynch on NASDAQ with an approximate sale date of 08/13/2025. The company reports 66,295,184 shares outstanding.
The filing also discloses recent sales by the same seller: 11,366 shares sold on 06/13/2025 for $165,930.95 and 11,366 shares sold on 07/14/2025 for $165,878.90. The filer affirms they are not aware of undisclosed material information and includes the standard signature/representation language required by Rule 144.
Mineralys Therapeutics is a clinical-stage biopharmaceutical company developing lorundrostat, an oral aldosterone synthase inhibitor for cardiorenal conditions. Two pivotal trials (Launch-HTN and Advance-HTN) met their primary endpoints with clinically meaningful, placebo-adjusted reductions in systolic blood pressure: Launch-HTN pooled 50 mg showed a placebo-adjusted reduction of ~9.1 mmHg at week 6 and ~11.6 mmHg at week 12; Advance-HTN demonstrated a placebo-adjusted ~7.9 mmHg reduction in 24-hour ambulatory systolic BP at week 12. A Phase 2 Explore-CKD crossover trial reported a placebo-adjusted systolic BP reduction of 7.5 mmHg (p=0.0024) and a 25.6% placebo-adjusted reduction in UACR (p=0.0015).
Safety signals included confirmed hyperkalemia in some cohorts (Launch-HTN confirmed rates up to 1.1%; Advance-HTN confirmed up to 3.2%; Explore-CKD 5% on drug) and modest mean eGFR declines in Explore-CKD. As of June 30, 2025, the company held $324.9 million in cash, cash equivalents, and investments, recorded a six-month net loss of $85.5 million, used $75.7 million of cash in operations in the six months, and had an accumulated deficit of $388.0 million. Management plans a pre-NDA meeting with the FDA in Q4 2025 and states current funds are sufficient for at least twelve months.
Mineralys Therapeutics, Inc. furnished a press release announcing its financial results for the quarter ended June 30, 2025 and provided a corporate update; the press release is attached to this Form 8-K as Exhibit 99.1. The Form 8-K states the exhibit is furnished and therefore not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference in other filings except as expressly noted.
The filing confirms the company鈥檚 common stock trades under MLYS on Nasdaq and indicates the registrant qualifies as an emerging growth company. No financial tables or numerical results are included in the 8-K text itself; readers must consult Exhibit 99.1 for the full financial details and corporate update.
FAQ
What is the current stock price of Mineralys Therapeutics (MLYS)?
What is the market cap of Mineralys Therapeutics (MLYS)?
